Fidelity Investments
ARCT icon

Fidelity Investments’s Arcturus Therapeutics ARCT Stock Holding History

Fidelity Investments’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
19,542
+14,921
+323% +$118K ﹤0.01% 3858
2026
Q1 		$35.7K Buy
4,621
+1,385
+43% +$10.1K ﹤0.01% 4264
2025
Q4 		$19.8K Sell
3,236
-130,639
-98% -$1.41M ﹤0.01% 4468
2025
Q3 		$2.47M Sell
133,875
-47,751
-26% -$767K ﹤0.01% 2475
2025
Q2 		$2.36M Sell
181,626
-80,384
-31% -$951K ﹤0.01% 2434
2025
Q1 		$2.77M Sell
262,010
-186,801
-42% -$2.97M ﹤0.01% 2344
2024
Q4 		$7.62M Buy
448,811
+5,803
+1% +$109K ﹤0.01% 2028
2024
Q3 		$10.3M Sell
443,008
-112,516
-20% -$2.41M ﹤0.01% 1914
2024
Q2 		$13.5M Sell
555,524
-66,334
-11% -$2.01M ﹤0.01% 1780
2024
Q1 		$21M Sell
621,858
-242,500
-28% -$8.59M ﹤0.01% 1636
2023
Q4 		$27.3M Sell
864,358
-75,923
-8% -$1.8M ﹤0.01% 1508
2023
Q3 		$24M Buy
940,281
+74,081
+9% +$2.28M ﹤0.01% 1517
2023
Q2 		$24.8M Buy
866,200
+37,808
+5% +$1.03M ﹤0.01% 1555
2023
Q1 		$19.9M Sell
828,392
-81,851
-9% -$1.47M ﹤0.01% 1610
2022
Q4 		$15.4M Sell
910,243
-44,082
-5% -$769K ﹤0.01% 1720
2022
Q3 		$14.1M Buy
954,325
+33,568
+4% +$563K ﹤0.01% 1750
2022
Q2 		$14.5M Sell
920,757
-39
-0% -$765 ﹤0.01% 1785
2022
Q1 		$24.8M Buy
920,796
+272
+0% +$6.94K ﹤0.01% 1693
2021
Q4 		$34.1M Sell
920,524
-152,453
-14% -$6.21M ﹤0.01% 1574
2021
Q3 		$51.3M Buy
1,072,977
+342,687
+47% +$15.4M ﹤0.01% 1400
2021
Q2 		$24.7M Hold
730,290
– – ﹤0.01% 1756
2021
Q1 		$30.2M Hold
730,290
– – ﹤0.01% 1617
2020
Q4 		$31.7M Sell
730,290
-39,710
-5% -$2.69M ﹤0.01% 1502
2020
Q3 		$33M Buy
770,000
+95,000
+14% +$4.72M ﹤0.01% 1357
2020
Q2 		$31.6M Buy
675,000
+275,000
+69% +$9.48M ﹤0.01% 1357
2020
Q1 		$5.44M Hold
400,000
– – ﹤0.01% 1913
2019
Q4 		$4.35M Hold
400,000
– – ﹤0.01% 2084
2019
Q3 		$4.11M Buy
+400,000
New +$4.32M ﹤0.01% 2102

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments's ARCT Position: Q2 2026 in Review

Fidelity Investments increased its Arcturus Therapeutics (ARCT) stake by 323% in Q2 2026, buying an estimated $118K and bringing the position to 19,542 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #3858.

Fidelity Investments first reported a position in ARCT in Q3 2019 and has held it in 28 quarters since. The position peaked at $51.3M in Q3 2021. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Fidelity Investments held 19,542 shares of Arcturus Therapeutics worth $131K as of Q2 2026.
  • Fidelity Investments bought 14,921 Arcturus Therapeutics shares in Q2 2026, an estimated $118K.
  • Arcturus Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3858 holding.
  • Fidelity Investments first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Fidelity Investments's Arcturus Therapeutics position peaked at $51.3M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.